Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

NCT00606307 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
29
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Italfarmaco